Literature DB >> 6716401

Intensely potent morpholinyl anthracyclines.

E M Acton, G L Tong, C W Mosher, R L Wolgemuth.   

Abstract

3'-Deamino-3'-(3-cyano-4-morpholinyl)doxorubicin is a new analogue that is 100 to 1000 times more potent than doxorubicin against tumors in cell culture or in mice, that is active by intraperitoneal, intravenous, or oral dosing, and that does not produce chronic myocardial lesions in mice. This analogue was encountered in studies on the reductive alkylation of doxorubicin and daunorubicin with 2,2' - oxybis [acetaldehyde], which constructs a morpholino ring incorporating the amino N. The morpholinyl nitrile byproducts are separated by virtue of their nonbasicity from the expected morpholino derivatives. The 13-dihydro and 5-imino derivatives are also described in this important new class of anthracyclines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6716401     DOI: 10.1021/jm00371a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Heterocycles via intramolecular platinum-catalyzed propargylic substitution.

Authors:  Qiren Liang; Jef K De Brabander
Journal:  Tetrahedron       Date:  2011-07-08       Impact factor: 2.457

2.  Neurotoxicity and dermatotoxicity of cyanomorpholinyl adriamycin.

Authors:  S C Cramer; R H Rhodes; E M Acton; Z A Tökés
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Thermal stability of DNA adducts induced by cyanomorpholinoadriamycin in vitro.

Authors:  C Cullinane; D R Phillips
Journal:  Nucleic Acids Res       Date:  1993-04-25       Impact factor: 16.971

5.  Comparative cytotoxicities of various morpholinyl anthracyclines.

Authors:  D G Streeter; D L Taylor; E M Acton; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group.

Authors:  T G Burke; A C Sartorelli; T R Tritton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.

Authors:  R Perez-Soler; Y H Ling; Y Zou; W Priebe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

9.  Induction of malignant transformation in vitro and mammary tumors in rats by two new potent anthracycline antitumor antibiotics, morpholinodaunomycin and cyanomorpholinoadriamycin.

Authors:  J Westendorf; U Mohr; H Marquardt
Journal:  Cell Biol Toxicol       Date:  1987-03       Impact factor: 6.691

10.  The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.

Authors:  W T van der Graaf; N H Mulder; C Meijer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.